-
WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio
•
China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic licensing agreement with compatriot firm Hangzhou DAC Biotechnology Co., Ltd, an antibody drug conjugate (ADC) specialist, and US-based Aadi Bioscience, Inc. (NASDAQ: AADI). The deal grants Aadi Bio global d2018evelopment and commercialization rights to a…
